All NewsBio/Pharma News
All PublicationsPharmTechPharmTech Europe
MarketplaceICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksWhitepapers
Webcasts
All VideosAsk the ExpertBehind The HeadlinesBuy, Sell, HoldDrug Digest VideosDrug Solutions PodcastPeer ExchangeSexy ScienceTech Talk
Conference CoverageConference ListingEvents
Subscribe
AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
Spotlight -
  • Analytics
  • Dosage Forms
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Webcasts
    • Subscribe
Advertisement

Controlled-Release Formulations a Popular Strategy for Generic-Drug Companies

September 10, 2009
By Pharmaceutical Technology Editors
News
Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

Generic-drug companies are increasingly viewing the development of controlled-release formulations as a way of obtaining a competitive edge, according to a report published by Espicom Business Intelligence in late August 2009.

Generic-drug companies are increasingly viewing the development of controlled-release formulations as a way of obtaining a competitive edge, according to a report published by Espicom Business Intelligence in late August 2009. Interest in these formulations is partly inspired by the number of controlled-release drugs that will soon lose patent protection.
 
The report, titled “Emerging Opportunities in Controlled-Release Generic Drugs,” says that several factors make developing controlled-release drugs an attractive strategy for generics companies. Technical hurdles make these formulations difficult to develop, and the companies that create and market them have fewer competitors and can charge higher prices than those charged for instant-release formulations. The controlled-release drugs examined in the report had combined sales of more than $15 billion in 2008.
 
Companies are beginning to consider controlled-release delivery early in the product life cycle, rather than developing it as a product’s patent expiration nears, according to the report. Some companies are marketing immediate- and controlled-release versions of new drugs simultaneously.
 
Although many controlled-release formulations are protected by patents, US companies frequently file Paragraph IV certifications under the Hatch–Waxman Act, and the patents’ validity is often the subject of litigation. Litigation sometimes yields agreements between generic-drug companies and innovators that allow the limited introduction of a generic drug before the reference product’s patent expires. The agreements can benefit innovator companies by limiting generic competition and revenue loss. The agreements can provide generic-drug companies with early market entry and a period of reduced competition.
 
Wyeth’s (Madison, NJ) popular Effexor XR (venlafaxine) has been the subject of much recent patent litigation. The company initiated several lawsuits after various firms filed abbreviated new drug applications (ANDAs) with the US Food and Drug Administration for generic versions of Effexor XR. Cases against Sandoz (Holzkirchen, Germany), Mylan (Canonsburg, PA), Wockhardt (Mumbai), Biovail (Mississauga, Canada), Torrent (Ahmedabad, India), and Apotex (Toronto) remained outstanding as of July 2009. Impax (Hayward, CA) and Mylan received tentative approval for their ANDAs for generic, controlled-release venlafaxine capsules.
 
FDA approved Osmotica’s (Wilmington, NC) new drug application for a controlled-release venlafaxine tablet. Wyeth filed a patent-infringement lawsuit against the company and ultimately granted Osmotica a license to manufacture the drug in exchange for a royalty on sales. Wyeth also settled litigation against Impax, Lupin (Mumbai), Anchen Pharmaceuticals (Irvine, CA), and Teva Pharmaceutical Industries (Petach Tikva, Israel).
 
See related PharmTech articles:

Down the Track: Different Speeds with Multiple APIs (Pharmaceutical Technology)

A Tale of Two Techniques (online exclusive)

Implications of the Pending Pfizer-Wyeth Mega Merger (PharmTech Sourcing and Management)

 

Recent Videos
Behind the Headlines, Episode 18
Drug Digest: Patient Preference Drives Solid Dosage Trends
Behind the Headlines, Episode 17
Related Content

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Aenova Adds Cold Chain Warehouse to Latina, Italy Site

Susan Haigney
June 27th 2025
Article

The new building expands on the company’s supply chain solutions for biologics and temperature-sensitive pharmaceuticals.


Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.


3D Rendering of CAR - Chimeric Antigen Receptor Between T-Cell and Cancer Cell | Image Credit: © Alpha Tauri 3D - stock.adobe.com

Priothera Awarded €1.7M in Innovation Contest for Hematologic Malignancy Treatments

Patrick Lavery
June 26th 2025
Article

The company’s mocravimod, a novel oral S1P receptor, is being evaluated for its efficacy as an addition to CAR-T cell therapies.


Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
May 28th 2024
Podcast

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.


Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

European Pharmacopoeia Goes Digital

Susan Haigney
June 25th 2025
Article

The 12th edition of the European Pharmacopoeia will be an all-digital, redesigned, user-friendly issue.


The mRNA or messenger Ribonucleic Acid white text for medical or outbreak concept 3d rendering | Image Credit: ©niphon - adobe.stock.com

Looking Beyond mRNA-based COVID-19 Vaccines to Innovative Therapeutics

Cheryl Barton
June 24th 2025
Article

mRNA technologies offer great promise in immunotherapy and non-immunogenic applications.

Related Content

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Aenova Adds Cold Chain Warehouse to Latina, Italy Site

Susan Haigney
June 27th 2025
Article

The new building expands on the company’s supply chain solutions for biologics and temperature-sensitive pharmaceuticals.


Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.


3D Rendering of CAR - Chimeric Antigen Receptor Between T-Cell and Cancer Cell | Image Credit: © Alpha Tauri 3D - stock.adobe.com

Priothera Awarded €1.7M in Innovation Contest for Hematologic Malignancy Treatments

Patrick Lavery
June 26th 2025
Article

The company’s mocravimod, a novel oral S1P receptor, is being evaluated for its efficacy as an addition to CAR-T cell therapies.


Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
May 28th 2024
Podcast

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.


Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

European Pharmacopoeia Goes Digital

Susan Haigney
June 25th 2025
Article

The 12th edition of the European Pharmacopoeia will be an all-digital, redesigned, user-friendly issue.


The mRNA or messenger Ribonucleic Acid white text for medical or outbreak concept 3d rendering | Image Credit: ©niphon - adobe.stock.com

Looking Beyond mRNA-based COVID-19 Vaccines to Innovative Therapeutics

Cheryl Barton
June 24th 2025
Article

mRNA technologies offer great promise in immunotherapy and non-immunogenic applications.

About Us
Advertise
Contact Us
Editorial Info
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.